Suppr超能文献

炎症性肠病患儿向成人医学过渡的临床和遗传特征:单中心十年经验

Clinical and Genetic Characteristics of Pediatric Patients with Inflammatory Bowel Disease Transitioning to Adult Medicine: A Single-Center Ten-Year Experience.

作者信息

Mocci Giammarco, Orrù Giorgia, Onidi Francesca Maria, Corpino Mara, Marongiu Antonella, Argiolas Giovanni Maria, Runfola Matteo, Manunza Romina, Locci Giorgia, Tamponi Elisabetta, Zolfino Teresa, Usai Satta Paolo, Muscas Alessandro, Rossino Rossano, Savasta Salvatore, Congia Mauro

机构信息

Division of Gastroenterology, "Brotzu" Hospital, 09047 Cagliari, Italy.

Department of Medical Sciences and Public Health, University of Cagliari, 09042 Cagliari, Italy.

出版信息

J Clin Med. 2025 May 27;14(11):3741. doi: 10.3390/jcm14113741.

Abstract

: Inflammatory bowel diseases (IBDs) comprise a group of chronic idiopathic disorders, including ulcerative colitis (UC), Crohn's disease (CD), and indeterminate colitis (IC). Complex genetic factors, in addition to environmental triggers, have been shown to play a fundamental role in the pathogenesis of IBD, contributing to disease susceptibility. The transition of adolescents with inflammatory bowel disease (IBD) to adult care represents a significant challenge for patients, their families, and healthcare providers. Approximately 25% of individuals with IBD receive a diagnosis before the age of 16, and this population is at increased risk for adverse clinical outcomes. As a result, the transition of care has garnered substantial attention in the scientific and clinical communities over the past decade. This study aims to analyze a cohort of pediatric Sardinian patients with IBD to assess clinical characteristics at diagnosis and at the time of transition and determine potential correlations between NOD2/CARD15 gene variants and HLA class II with the disease phenotype. : From January 2014 to August 2024, we performed an observational, cross-sectional study that included pediatric patients with IBD enrolled in the only pediatric IBD reference center in Sardinia. Data were obtained from the patients' medical records and from a questionnaire administered at the inclusion visit. In addition, we genotyped a portion of our cohort for the Leu1007fsinsC (SNP13), Gly908Arg (SNP12), and Arg702Trp (SNP8) variants of the NOD2/CARD15 gene, as well as for HLA-DRB1, -DQA1, and -DQB1 class II genes. The obtained results were compared with pediatric data from the national epidemiological IBD registry and existing literature. : Seventy-one IBD patients were enrolled (UC 43, CD 28, M 34, F 37). Median age at diagnosis was 12.2 years (IQR 2-17). After a median disease duration of 5 years (IQR: 1-16), only three UC patients experienced proximal extension of proctitis or left-sided colitis, and no CD patients experienced new localizations of disease. Fifteen patients developed extraintestinal manifestations. No significant difference was found in median diagnostic delay (DD) between UC [4 months (IQR: 1-84)] and CD patients [4.5 months (IQR: 1-48)]. At the transition visit, overall, twenty-nine patients (42%) were exposed to one biologic agent (vs. 3% at baseline; < 0.02); 3 patients (4%) were exposed to two or more biologic agents. 7% of patients (5/71) underwent surgery. By comparing the distribution of NOD2/CARD15 SNPs between pediatric patients and an adult CD population, we found a significant association between gene allelic variants and pediatric onset ( = 0.00048). Our study also revealed a statistically significant association between Sardinian pediatric patients carrying NOD2/CARD15 mutations and early-onset CD ( < 0.009492), along with a stenosing phenotype ( < 0.024) and increased surgical risk ( < 0.026). No significant associations were observed between HLA class II alleles and IBD in our population. : Our results provide important insights into the clinical and epidemiological features of the pediatric IBD population. In addition, our study highlights the significant role of NOD2/CARD15 gene polymorphisms in pediatric onset CD. These variants influence the age of onset and disease phenotype, characterized by greater severity and a higher risk of surgical intervention in pediatric patients.

摘要

炎症性肠病(IBDs)是一组慢性特发性疾病,包括溃疡性结肠炎(UC)、克罗恩病(CD)和不确定性结肠炎(IC)。除环境触发因素外,复杂的遗传因素在IBD的发病机制中也起着重要作用,影响疾病易感性。炎症性肠病(IBD)青少年患者向成人护理的过渡对患者及其家庭以及医疗服务提供者来说是一项重大挑战。约25%的IBD患者在16岁之前被诊断出,这一群体出现不良临床结局的风险增加。因此,在过去十年中,护理过渡问题在科学界和临床界引起了广泛关注。本研究旨在分析一组撒丁岛儿科IBD患者,以评估诊断时和过渡时的临床特征,并确定NOD2/CARD15基因变异与HLA II类基因与疾病表型之间的潜在相关性。

从2014年1月至2024年8月,我们进行了一项观察性横断面研究,纳入了撒丁岛唯一的儿科IBD参考中心登记的儿科IBD患者。数据来自患者的病历以及纳入访视时发放的问卷。此外,我们对队列中的一部分患者进行了NOD2/CARD15基因的Leu1007fsinsC(SNP13)、Gly908Arg(SNP12)和Arg702Trp(SNP8)变异以及HLA-DRB1、-DQA1和-DQB1 II类基因的基因分型。将获得的结果与国家IBD流行病学登记处的儿科数据以及现有文献进行比较。

共纳入71例IBD患者(UC 43例,CD 28例,男性34例,女性37例)。诊断时的中位年龄为12.2岁(四分位间距2 - 17岁)。疾病中位持续时间为5年(四分位间距:1 - 16年),只有3例UC患者出现直肠炎近端扩展或左侧结肠炎,没有CD患者出现新的疾病定位。15例患者出现肠外表现。UC患者[4个月(四分位间距:1 - 84)]和CD患者[4.5个月(四分位间距:1 - 48)]的中位诊断延迟(DD)无显著差异。在过渡访视时,总体上,29例患者(42%)接受了一种生物制剂治疗(基线时为3%;<0.02);3例患者(4%)接受了两种或更多种生物制剂治疗。7%的患者(5/71)接受了手术。通过比较儿科患者和成人CD人群中NOD2/CARD15单核苷酸多态性的分布,我们发现基因等位变异与儿科发病之间存在显著关联(P = 0.00048)。我们的研究还揭示,携带NOD2/CARD15突变的撒丁岛儿科患者与早发性CD(P < 0.009492)、狭窄表型(P < 0.024)和手术风险增加(P < 0.026)之间存在统计学显著关联。在我们的人群中,未观察到HLA II类等位基因与IBD之间存在显著关联。

我们的结果为儿科IBD人群的临床和流行病学特征提供了重要见解。此外,我们的研究强调了NOD2/CARD15基因多态性在儿科发病CD中的重要作用。这些变异影响发病年龄和疾病表型,其特征是儿科患者病情更严重且手术干预风险更高。

相似文献

本文引用的文献

9
Systematic Review of Diagnostic Delay for Children With Inflammatory Bowel Disease.炎症性肠病患儿诊断延迟的系统评价
J Pediatr Gastroenterol Nutr. 2023 Mar 1;76(3):304-312. doi: 10.1097/MPG.0000000000003670. Epub 2022 Dec 1.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验